Mitochondrial-derived peptide
MOTS-c
A mitochondrial-derived research peptide whose biological interest has moved far ahead of human clinical evidence.
Why it is discussed
Metabolic, exercise, and healthy-aging claims
MOTS-c is discussed for glucose metabolism, exercise capacity, weight, and healthy-aging claims because of preclinical mitochondrial-signaling research. FDA reports no identified human exposure data for drug products containing MOTS-c, so human benefits and safety remain unestablished.
What it is
A short peptide linked to mitochondrial signaling.
MOTS-c is a 16-amino-acid peptide identified from a short coding sequence within the mitochondrial 12S ribosomal-RNA region. Mitochondria help cells process energy, but MOTS-c is a signaling peptide—not a mitochondrion, a fuel, or a replacement for exercise.
How it works
Experimental links between nutrient sensing and gene regulation.
In cell experiments, MOTS-c altered folate-related and purine metabolism. This increased AICAR, a metabolite associated with activation of AMPK, a cellular energy-sensing enzyme. Mouse experiments also examined insulin sensitivity and metabolic responses. These are preclinical observations, not established effects of a consumer product.
A separate study found that metabolic stress could move MOTS-c into the cell nucleus, where it influenced stress-response gene regulation. This suggests communication between mitochondrial signals and nuclear activity rather than simply increasing energy production.
The proposed pathways do not establish that administering synthetic MOTS-c reproduces endogenous signaling in humans. Clinical benefits, tissue delivery, long-term safety, and equivalence of unverified preparations require separate evidence.
Scientific / evidence sources
Evidence at a glance
What is established—and what is not.
Preclinical evidence without established human exposure
Preclinical mitochondrial-signaling research supports hypotheses involving metabolism and exercise biology.
FDA reports no identified human exposure data for drug products containing MOTS-c, so human benefits and safety remain unestablished.
Regulatory status
Canada and the United States are checked separately.
Health Canada lists injectable MOTS-c among unauthorized peptide drugs and advises consumers not to buy or use them.
No FDA-approved product. FDA cites absent human exposure data plus peptide characterization and immunogenicity concerns.
Regulatory status describes product authorization and relevant regulatory context. It is not a complete legal opinion about possession, importation, prescribing, sale, or professional practice.
If you are reviewing a product report
The molecule profile and the testing report answer different questions.
This page summarizes evidence and regulatory context. A laboratory report may address identity, purity, or quantity for one submitted sample; it does not transfer clinical evidence or product authorization.